The United Laboratories International Holdings Limited (HK:3933)
:3933
Want to see HK:3933 full AI Analyst Report?
3933 Stock Chart & Stats
HK$11.74
HK$0.26(2.23%)
At close: 4:00 PM EST
HK$11.74
HK$0.26(2.23%)
Day’s Range― - ―
52-Week RangeHK$8.24 - HK$17.98
Previous CloseN/A
Volume6.42M
Average Volume (3M)9.98M
Market Cap
HK$16.69B
Enterprise ValueHK$8.75B
Total Cash (Recent Filing)HK$11.24B
Total Debt (Recent Filing)HK$4.99B
Price to Earnings (P/E)6.8
Beta0.82
Next Earnings
Aug 27, 2026EPS Estimate
0.5Next Dividend Ex-DateN/A
Dividend Yield5.11%
Share Statistics
EPS (TTM)1.14
Shares Outstanding1,973,026,500
10 Day Avg. Volume7,816,257
30 Day Avg. Volume9,977,158
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.13
Price to Sales (P/S)1.49
P/FCF Ratio22.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$16.23Price Target Upside38.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.64
Revenue Forecast (FY)HK$12.79B
Bulls Say, Bears Say
Bulls Say
Healthy Gross MarginA sustained gross margin near 42% indicates durable product-level profitability and pricing power in the portfolio. This margin buffer supports reinvestment in R&D and manufacturing and helps absorb cost pressure, aiding long-term earnings resilience.
Conservative Leverage And Asset GrowthLow to moderate debt ratios and steady equity growth provide financial flexibility to fund R&D, capex and M&A without heavy refinancing risk. A conservatively levered balance sheet supports stability across industry cycles and limits solvency risk.
Integrated R&D And ManufacturingVertical integration across R&D, manufacturing and commercialization creates control over quality, cost and supply. This capability supports faster product scale-up, margin maintenance and competitive moat versus pure-play contract models over a multi-quarter horizon.
Bears Say
Recent Revenue DeclineA near-term reversal from multi-year growth to an ~8.7% decline signals demand or commercialization setbacks. Sustained top-line weakness can pressure scale economics, R&D funding and long-term market share unless new product pickups or channel recoveries occur.
Margin Compression And Falling ROECompression of margins and a meaningful ROE drop reduce returns on invested capital and indicate weakening profitability quality. Persistently lower margins limit internal funding capacity and challenge management to restore capital efficiency over coming quarters.
Volatile Cash Conversion / Low FCFWeak and volatile free cash flow relative to earnings undermines cash available for dividends, capex and debt reduction. If cash conversion remains inconsistent, the company may face constraints financing growth initiatives or face pressure on payout sustainability.
The United Laboratories International Holdings News
3933 FAQ
What was The United Laboratories International Holdings Limited’s price range in the past 12 months?
The United Laboratories International Holdings Limited lowest stock price was HK$8.24 and its highest was HK$17.98 in the past 12 months.
What is The United Laboratories International Holdings Limited’s market cap?
The United Laboratories International Holdings Limited’s market cap is HK$16.69B.
When is The United Laboratories International Holdings Limited’s upcoming earnings report date?
The United Laboratories International Holdings Limited’s upcoming earnings report date is Aug 27, 2026 which is in 77 days.
How were The United Laboratories International Holdings Limited’s earnings last quarter?
The United Laboratories International Holdings Limited released its earnings results on Mar 24, 2026. The company reported HK$0.127 earnings per share for the quarter, beating the consensus estimate of HK$0.069 by HK$0.058.
Is The United Laboratories International Holdings Limited overvalued?
According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Undervalued.
Does The United Laboratories International Holdings Limited pay dividends?
The United Laboratories International Holdings Limited pays a Annually dividend of HK$0.301 which represents an annual dividend yield of 5.11%. See more information on The United Laboratories International Holdings Limited dividends here
What is The United Laboratories International Holdings Limited’s EPS estimate?
The United Laboratories International Holdings Limited’s EPS estimate is 0.5.
How many shares outstanding does The United Laboratories International Holdings Limited have?
The United Laboratories International Holdings Limited has 1,973,026,500 shares outstanding.
What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?
The United Laboratories International Holdings Limited reported an EPS of HK$0.127 in its last earnings report, beating expectations of HK$0.069. Following the earnings report the stock price went up 2.277%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?
Currently, no hedge funds are holding shares in HK:3933
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
The United Laboratories International Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.38%
12-Months-Change
Fundamentals
Return on Equity
12.65%
Trailing 12-Months
Asset Growth
24.94%
Trailing 12-Months
Company Description
The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
3933 Stock 12 Month Forecast
Average Price Target
HK$16.23
▲(38.26% Upside)
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---